Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 19Neoplasm Metastasis 6Brain Neoplasms 4Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Lung Neoplasms 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Salivary Gland Neoplasms 1Rare Tumour 1Prostatic Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neuroma, Acoustic 1Neurofibromatosis 2 1Meningioma 1Malignant Female Reproductive System Neoplasm 1Hemangiosarcoma 1HER2-positive Breast Cancer 1HER2 Positive Breast Carcinoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Ependymoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Lobular 1Carcinoma 1

Interventions

Carboplatin 195Cisplatin 117Paclitaxel 107Pemetrexed 106Docetaxel 96Gemcitabine 89Radiotherapy 83Erlotinib Hydrochloride 58Bevacizumab 55Etoposide 49durvalumab 39pembrolizumab 38Nivolumab 31Specimen Handling 30Magnetic Resonance Spectroscopy 30Irinotecan 27Radiosurgery 26osimertinib 24Gefitinib 24Drug Therapy 23Vinorelbine 22atezolizumab 20Topotecan 20Radiation 16Cetuximab 16Taxes 15Surgical Procedures, Operative 14Neoadjuvant Therapy 13Filgrastim 13Chemotherapy, Adjuvant 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Lung Neoplasms × neratinib × Clear all
NCT01827267 2018-07-03

Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

Puma Biotechnology, Inc.

Phase 2 Completed
62 enrolled 12 charts
Thoracic

Lung Neoplasms

NCT00266877 2018-04-13

Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer

Puma Biotechnology, Inc.

Phase 2 Completed
172 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡